Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year

Impact · against what's priced in

Praxis Precision Medicines shows strong fundamental health with a cash runway extending into 2028 and significant institutional backing from Baker Bros. The submission of two NDAs for ulixacaltamide and relutrigine marks a critical transition toward potential commercialization, though much of the recent 300% price surge likely reflects this optimism.

PRAX+0.50

No priced-in read yet